ClinicalTrials.gg
Status unknownNCT04639375Updated Aug 27, 2021

Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)

A Phase 4 interventional study of Vaccinated with polio vaccine (IPV) in SARS-CoV-2, sponsored by E-MO Biology Inc. Status unknown at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-27.

Sponsored by E-MO Biology Inc · Phase 4, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1. Blood specimens collected pre-inoculation will be tested for cross-reactivity to poliovirus and SARS-CoV-2 by Western blot. An additional specimen will be collected on Day 28 post-inoculation and, likewise tested for cross-reactivity to poliovirus and SARS-CoV-2.

The number of subjects with an immune response to SARS-CoV-2 antigens following inoculation with IPV will be summarized.

Read the detailed description

A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1. Blood specimens collected pre-inoculation will be tested for cross-reactivity to poliovirus and SARS-CoV-2 by Western blot. An additional specimen will be collected on Day 28 post-inoculation and, likewise tested for cross-reactivity to poliovirus and SARS-CoV-2.

If the results from this study demonstrate that polio vaccine induces an immune response against both the immunogen (poliovirus) and SARS-CoV-2, the study may be amended after consultation with the Center for Biologics evaluation and research (CBER), to enroll an additional 275 subjects. Expansion of the original cohort will be stratified by age and race/ethnicity.

The number of subjects with an immune response to SARS-CoV-2 antigens following inoculation with IPV will be summarized.

Vaccination for poliomyelitis is part of routine childhood vaccination. Only IPV has been administered in the United States since the year 2000 as a series of 4 inoculations in childhood inducing an immunity which, although protective for years, wans over time and is, for the most part, undetectable in adults unless a booster is administered. United States residents are advised to receive a booster prior to travelling to countries where polio disease remains endemic.

Inactivated vaccines against RNA viruses (including Poliovirus and coronavirus) induce an immune response that recognizes the non-structural antigens of the inactivated viral particle. There is extensive homology between Poliovirus and SARS-CoV-2 RNA-dependent-RNA-polymerase (RdRp) both within the coding regions and illustrated in the 3-dimensional modeling. The homology between the viral epitopes may be sufficient such that adults who receive a polio booster develop an immune response that cross-reacts with SARS-CoV-2. Consequently, the neutralizing activity of antibodies raised to SARS-CoV-2 RdRp will be evaluated.To evaluate and characterize the immune response to SARS-CoV-2 elicited in adults by IPV.

Primary Objective: To evaluate whether an immune response to SARS-CoV-2 RdRp is induced in adults receiving a booster inoculation of IPV.

Secondary Objectives:: To evaluate the neutralizing activity of antibodies raised to SARS-CoV-2 RdRp

This is a single-site study in a clinic in San Diego California that routinely diagnoses and manages patients with COVID-19.

02

Conditions studied

  • SARS-CoV-2
03

In context

Lead sponsor

This is the only study on the registry with E-MO Biology Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 18-80
  4. Female subjects of must have a negative pregnancy test (point-of-care dipstick) prior to being vaccinated and be willing to use an effective method of from the time of entry into the study and for 30 days following vaccination
  5. In good general health with no active infectious disease as evidenced by medical history and directed physical examination.

Exclusion criteria

Exclusion Criteria:

  1. Known allergic reactions to components of the polio vaccine
  2. Febrile illness within 14 days
  3. Positive for SARS-CoV-2 antigenemia at any time prior to screening1
  4. Positive for SARS-CoV-2 antibodies at any time prior to screening1
  5. Subjects with fever > 101o F at screening
  6. Subjects who respond yes to any of the following question:

    Have you experienced any of the following symptoms in the past 48 hours (14):

    • fever or chills
    • cough
    • shortness of breath or difficulty breathing
    • fatigue
    • muscle or body aches
    • headache
    • new loss of taste or smell
    • sore throat
    • congestion or runny nose
    • nausea or vomiting
    • diarrhea
  7. Treatment with an drug or other intervention within the 90 days prior to enrollment in this study
  8. Inoculation with polio vaccine within the last 12 years
  9. Women who are pregnant or breast feeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Vaccinated with polio vaccine (IPV)

    All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States

    Biological: Vaccinated with polio vaccine (IPV)

Interventions

  • BiologicalVaccinated with polio vaccine (IPV)

    poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination

    Percentage of all subjects vaccinated with IPV with antibodies to SARS-CoV-2 RdRp

    Time frame: Day 28

Secondary outcomes

  1. Determination of neutralizing titer of antibodies raised to SARS-CoV-2 following vaccination with polio vaccine

    Antibodies raised following IPV vaccination will be evaluated for neutralizing titer to both polio virus and SARS-CoV-2

    Time frame: Day 28

07

Study locations

1 site
  • Rac Ii Md
    National City, California 91950, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Jun 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2020
First posted
Nov 20, 2020
StartActual
Nov 15, 2020
Primary completionActual
Jun 12, 2021
CompletionEst.
Jun 12, 2022
Last update
Aug 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04639375
Lead sponsor
E-MO Biology Inc
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
Nov 15, 2020
Primary completion
Jun 12, 2021
Completion
Jun 12, 2022 (estimated)
Last update
Aug 27, 2021

Study contacts

John Andrews
study chair · E-MO Biology Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion